Harvey Gedeon

Unigen, a US developer of botanical and marine-derived compounds, has signed an exclusive product license and supply agreement with an Estée Lauder subsidiary for the development and commercialization of its proprietary natural ingredients.

Under the agreement, the financial details of which have not been disclosed, Unigen will grant Estée Lauder exclusive rights to its discoveries.

Harvey Gedeon, Executive Vice President Global Research, Development and Product Innovation for the Estée Lauder Companies, said that the company is already using one of Unigen’s discoveries in Clinique’s new products: Clinique Even Better Clinical Dark Spot Corrector and Clinique Derma White Clinical Brightening Essence.

We look forward to working with Unigen’s scientists to bring additional benefits to our other products and brands,” he added.

For the Estée Lauder Companies the agreement formalizes an important and commercially successful collaboration with one of the leading experts in discovery and development of proprietary natural ingredients for the dietary supplement, food, cosmetics, personal care and pharmaceutical industries.

"The greatest reward for scientists is to see their discovery successfully commercialized and provide meaningful benefits. We are delighted that a company with the Estée Lauder Companies’ stature and global reach has committed to showcase our scientists’ discoveries," said Ed Cannon, Unigen’s President and Chief Executive Officer.